Barry Skikne

5.5k total citations · 1 hit paper
105 papers, 3.7k citations indexed

About

Barry Skikne is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Barry Skikne has authored 105 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 93 papers in Hematology, 36 papers in Genetics and 22 papers in Molecular Biology. Recurrent topics in Barry Skikne's work include Acute Myeloid Leukemia Research (61 papers), Iron Metabolism and Disorders (17 papers) and Hematopoietic Stem Cell Transplantation (16 papers). Barry Skikne is often cited by papers focused on Acute Myeloid Leukemia Research (61 papers), Iron Metabolism and Disorders (17 papers) and Hematopoietic Stem Cell Transplantation (16 papers). Barry Skikne collaborates with scholars based in United States, France and Australia. Barry Skikne's co-authors include James D. Cook, Carol H. Flowers, Lawrence T. Goodnough, Carlo Brugnara, Roy D. Baynes, James D. Cook, Paul R. Schloerb, Sean Lynch, David Bodensteiner and Eric Laille and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Gastroenterology.

In The Last Decade

Barry Skikne

100 papers receiving 3.6k citations

Hit Papers

The quantitative assessment of body iron 2003 2026 2010 2018 2003 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The quantitative assessment of body iron
    2003 616 citations James D. Cook, Barry Skikne et al. Blood profile →

Peers

Barry Skikne
Robert T. Means United States
Andrew Mumford United Kingdom
Allan Rajamäki Finland
Andreas Hillarp Sweden
B. Skikne United States
Ángel F. Remacha Spain
I. Cavill United Kingdom
Joseph J. Shatzel United States
Peter F. Whitington United States
Ralph Carmel United States
Robert T. Means United States
Barry Skikne
Citations per year, relative to Barry Skikne Barry Skikne (= 1×) peers Robert T. Means

Countries citing papers authored by Barry Skikne

Since Specialization
Citations

This map shows the geographic impact of Barry Skikne's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barry Skikne with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barry Skikne more than expected).

Fields of papers citing papers by Barry Skikne

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Barry Skikne. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barry Skikne. The network helps show where Barry Skikne may publish in the future.

Co-authorship network of co-authors of Barry Skikne

This figure shows the co-authorship network connecting the top 25 collaborators of Barry Skikne. A scholar is included among the top collaborators of Barry Skikne based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Barry Skikne. Barry Skikne is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mansour, Razan, Nausheen Ahmed, Muhammad Umair Mushtaq, et al.. (2025). Efficacy and Safety of Daratumumab, Pomalidomide and Dexamethasone Compared to Daratumumab, Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Multicenter Real-World Experience. Clinical Lymphoma Myeloma & Leukemia. 26(2). 94–105.
2.
Menezes, Daniel L., Andrew H. Wei, Hartmut Döhner, et al.. (2023). P411: LONGITUDINAL CHARACTERIZATION OF MOLECULAR VARIANTS AT REMISSION AND RELAPSE: SUBANALYSIS OF THE QUAZAR AML-001 TRIAL. HemaSphere. 7(S3). e930876b–e930876b. 1 indexed citations
3.
Mansour, Razan, Hamza Hashmi, Aimaz Afrough, et al.. (2023). Efficacy of Daratumumab-Based Regimens in Anti-CD38 Treatment-Naïve Relapsed/Refractory Multiple Myeloma with High-Risk Cytogenetics. Blood. 142(Supplement 1). 1985–1985.
4.
Menezes, Daniel L., Wendy L. See, Alberto Risueño, et al.. (2023). Oral azacitidine modulates the bone marrow microenvironment in patients with acute myeloid leukaemia in remission: A subanalysis from the QUAZAR AML‐001 trial. British Journal of Haematology. 201(6). 1129–1143. 3 indexed citations
5.
Gaudy, Allison, et al.. (2023). Population Pharmacokinetics of Oral Azacitidine, and Exposure–Response Analysis in Acute Myeloid Leukemia. Clinical Pharmacology & Therapeutics. 114(4). 845–852. 4 indexed citations
6.
Mohyuddin, Ghulam Rehman, Brian McClune, Anurag K. Singh, et al.. (2020). Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation. Leukemia Research. 95. 106402–106402. 17 indexed citations
7.
Moyo, Tamara K., Justin M. Watts, Barry Skikne, et al.. (2019). Preliminary Results from a Phase II Study of the Combination of Pevonedistat and Azacitidine in the Treatment of MDS and MDS/MPN after Failure of DNA Methyltransferase Inhibition. Blood. 134(Supplement_1). 4236–4236. 10 indexed citations
8.
9.
Zeidan, Amer M., et al.. (2015). Economic burden associated with acute myeloid leukemia treatment. Expert Review of Hematology. 9(1). 79–89. 37 indexed citations
10.
Laille, Eric, Michael R. Savona, Bart L. Scott, et al.. (2013). Pharmacokinetics of different formulations of oral azacitidine (CC‐486) and the effect of food and modified gastric pH on pharmacokinetics in subjects with hematologic malignancies. The Journal of Clinical Pharmacology. 54(6). 630–639. 26 indexed citations
11.
Skikne, Barry, Kari Punnonen, Paul H. Caldron, et al.. (2011). Improved differential diagnosis of anemia of chronic disease and iron deficiency anemia: A prospective multicenter evaluation of soluble transferrin receptor and the sTfR/log ferritin index. American Journal of Hematology. 86(11). 923–927. 167 indexed citations
12.
Hershko, Chaim & Barry Skikne. (2009). Pathogenesis and Management of Iron Deficiency Anemia: Emerging Role of Celiac Disease, Helicobacter pylori, and Autoimmune Gastritis. Seminars in Hematology. 46(4). 339–350. 50 indexed citations
13.
Skikne, Barry. (2008). Serum transferrin receptor. American Journal of Hematology. 83(11). 872–875. 122 indexed citations
14.
15.
16.
Zhang, Jianghong, et al.. (2004). Localization of bone morphogenetic proteins (BMPs)-2, -4, and -6 within megakaryocytes and platelets. Bone. 35(6). 1316–1322. 86 indexed citations
17.
Cook, James D., Roy D. Baynes, & Barry Skikne. (1994). The Physiological Significance of Circulating Transferrin Receptors. Advances in experimental medicine and biology. 352. 119–126. 29 indexed citations
18.
Veldhuizen, Peter J. Van, James R. Neff, Mark D. Murphey, David Bodensteiner, & Barry Skikne. (1993). Decreased fibrinolytic potential in patients with idiopathic avascular necrosis and transient osteoporosis of the hip. American Journal of Hematology. 44(4). 243–248. 96 indexed citations
19.
Cook, James D., et al.. (1993). The clinical significance of serum transferrin receptor levels in sickle cell disease. British Journal of Haematology. 84(2). 301–304. 24 indexed citations
20.
Doolittle, Gary C., David Bodensteiner, Barry Skikne, & Mammo Amare. (1991). Therapy of aplastic anemia with sequential antithymocyte globulin and cyclosporin. American Journal of Hematology. 36(2). 144–146. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Robert T. Means Breakdown of academic impact, for papers by Andrew Mumford Breakdown of academic impact, for papers by Allan Rajamäki Breakdown of academic impact, for papers by Andreas Hillarp Breakdown of academic impact, for papers by B. Skikne Breakdown of academic impact, for papers by Ángel F. Remacha Breakdown of academic impact, for papers by I. Cavill Breakdown of academic impact, for papers by Joseph J. Shatzel Breakdown of academic impact, for papers by Peter F. Whitington Breakdown of academic impact, for papers by Ralph Carmel
Rankless by CCL
2026